Aquestive Therapeutics (NASDAQ:AQST) Insider Peter Boyd Sells 15,000 Shares

Key Points

• Insider Peter Boyd sold 15,000 shares of Aquestive Therapeutics at an average price of $5.30, resulting in a transaction total of $79,500.
• Aquestive Therapeutics saw its stock drop 7.6% to $5.01, with a market cap of approximately $499.60 million.
• Research analysts have given Aquestive Therapeutics a consensus rating of "Buy", with price targets ranging from $8.00 to $10.29.

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) insider Peter Boyd sold 15,000 shares of the business's stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $5.30, for a total transaction of $79,500.00. Following the completion of the sale, the insider owned 288,323 shares in the company, valued at approximately $1,528,111.90. This trade represents a 4.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Aquestive Therapeutics Trading Down 7.6%

AQST traded down $0.41 on Monday, hitting $5.01. The company had a trading volume of 3,306,780 shares, compared to its average volume of 1,621,107. The firm has a market cap of $499.60 million, a P/E ratio of -7.16 and a beta of 1.82. Aquestive Therapeutics, Inc. has a 1 year low of $2.12 and a 1 year high of $5.80. The company's fifty day moving average price is $3.98 and its 200 day moving average price is $3.25.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.04. The company had revenue of $10.00 million during the quarter, compared to analysts' expectations of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. On average, analysts predict that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Analyst Ratings Changes

AQST has been the topic of a number of recent research reports. HC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of Aquestive Therapeutics in a research note on Tuesday, June 17th. Oppenheimer boosted their price target on shares of Aquestive Therapeutics from $7.00 to $8.00 and gave the stock an "outperform" rating in a research note on Monday. Zacks Research upgraded shares of Aquestive Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Wednesday, August 13th. Finally, Lifesci Capital upgraded shares of Aquestive Therapeutics to a "strong-buy" rating in a research note on Wednesday, September 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $10.29.

Institutional Trading of Aquestive Therapeutics

A number of large investors have recently made changes to their positions in the company. Deutsche Bank AG increased its stake in Aquestive Therapeutics by 63.9% in the fourth quarter. Deutsche Bank AG now owns 61,989 shares of the company's stock valued at $221,000 after purchasing an additional 24,170 shares during the last quarter. Two Sigma Investments LP increased its stake in Aquestive Therapeutics by 31.5% in the fourth quarter. Two Sigma Investments LP now owns 175,952 shares of the company's stock valued at $626,000 after purchasing an additional 42,160 shares during the last quarter. Harvey Capital Management Inc. increased its stake in Aquestive Therapeutics by 86.8% in the first quarter. Harvey Capital Management Inc. now owns 499,570 shares of the company's stock valued at $1,449,000 after purchasing an additional 232,180 shares during the last quarter. ProShare Advisors LLC increased its stake in Aquestive Therapeutics by 79.8% in the fourth quarter. ProShare Advisors LLC now owns 25,232 shares of the company's stock valued at $90,000 after purchasing an additional 11,200 shares during the last quarter. Finally, Millennium Management LLC increased its stake in Aquestive Therapeutics by 111.2% in the fourth quarter. Millennium Management LLC now owns 87,227 shares of the company's stock valued at $311,000 after purchasing an additional 45,926 shares during the last quarter. 32.45% of the stock is currently owned by hedge funds and other institutional investors.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.